STOK News and Press, Stoke Therapeutics Inc. From 01/05/26

2026-01-05 07:05:47 ET from Canaccord Genuity issued a price target of $36.00 for STOK on 2026-01-05 11:53:37. The adjusted price target was set to $36.00. At the time of the announcement, STOK was trading at $30.9. The overall price target consensus is at $37.67 with hi...

2025-12-16 09:19:08 ET This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F stock portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 11/14/2025. The 13F portfolio value in...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of life&#...

—Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in seizure-free days, in addition to improvements in cognition, behavior and quality of lifeȁ...

2025-12-04 17:07:18 ET Read the full article on Seeking Alpha For further details see: Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating

CAMBRIDGE, Mass and BEDFORD, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Biogen Inc . (Nasdaq: BIIB) and Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, today announce...

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the...

– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative to children with typical development – – Findings underscore the urg...

Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatmen...

2025-11-04 17:16:03 ET More on Stoke Therapeutics Stoke Therapeutics: Vulnerable To Profit Taking Stoke Therapeutics names Ian F. Smith as CEO Seeking Alpha’s Quant Rating on Stoke Therapeutics Historical earnings data for Stoke Therapeutics Fi...